Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Melanotan I is ~2 hours circulating; implant provides 2-month depot release. This means dosing every 60 days (implant) or daily (injection) is typical to maintain stable levels. The half-life directly affects how long Melanotan I remains active and influences optimal injection timing.
What Is the Half-Life of Melanotan I?
The half-life of Melanotan I is ~2 hours circulating; implant provides 2-month depot release. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Melanotan I to maintain therapeutic blood levels.
What Does Melanotan I's Half-Life Mean for Dosing?
With a half-life of ~2 hours circulating; implant provides 2-month depot release, Melanotan I requires dosing every 60 days (implant) or daily (injection) to maintain stable levels. The standard dosage of 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) via subcutaneous implant (approved) or subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Melanotan I reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Melanotan I, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Melanotan I?
Optimal timing depends on your research goals. A half-life of ~2 hours circulating; implant provides 2-month depot release means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (every 60 days (implant) or daily (injection)) for more stable levels throughout the day.
How Does Melanotan I's Half-Life Compare to Similar Peptides?
Melanotan I is a Melanocortin-1 receptor (MC1R) agonist. Its half-life of ~2 hours circulating; implant provides 2-month depot release positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →Bottom Line: Melanotan I Half-Life and Dosing
Melanotan I has a half-life of ~2 hours circulating; implant provides 2-month depot release, supporting the standard protocol of 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) dosed every 60 days (implant) or daily (injection) over 60-day implant cycles; 4-8 weeks injection cycles.
Read our Melanotan I dosage guide for complete protocol details.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.